GET DAILY SIGNALSWhy Is Moderna (MRNA) Stock Down -6.71% Today?
Key Takeaways
- Moderna (MRNA) shares fell 6.71% to approximately $185.50, extending a multi-session selloff.
- The primary catalyst is continued "sell-the-news" pressure after full Phase 3 data for its personalized melanoma vaccine, intismeran autogene, came in below the lofty expectations priced into the stock.
- A William Blair downgrade to Market Perform from Outperform, citing valuation, added to the selling.
- The move is company-specific: broader biotech and equity indices were flat to slightly higher on the session.
- Traders are now watching Merck's earnings on Oct. 29 and Moderna's own report on Nov. 6 for pipeline and regulatory guidance.
- For additional detail, explore Price Targets, Earnings, and Forecast pages for this ticker.
- To see how automated strategies are positioning across the market, visit Trending AI Robots.
Opening Summary
Moderna, Inc. (MRNA), the Cambridge, Massachusetts-based messenger RNA (mRNA) drugmaker best known for its COVID-19 vaccine and now advancing a personalized cancer-vaccine platform, saw its shares decline sharply again on Tuesday. The stock closed the prior session at $198.85 and traded down roughly 6.71% to near $185.50 during the session. The decline extended a rout that began when detailed Phase 3 trial results for its Merck-partnered melanoma vaccine leaked ahead of a major oncology conference, deflating the elevated expectations that had driven a more than fivefold gain in the shares this year.
Catalyst Breakdown
Leaked Melanoma Data and a "Sell-the-News" Reaction
The dominant driver remains the full Phase 3 readout for intismeran autogene, the personalized mRNA cancer vaccine MRNA is developing with Merck (MRK). The INTerpath-001 trial met its primary endpoint, showing that combining intismeran with Merck's Keytruda reduced the risk of melanoma recurrence or death by 42% versus Keytruda alone. However, that figure fell short of the 49% reduction reported in the earlier Phase 2b study, and the distant-metastasis readout of 38% came in below bullish investor forecasts. Because the numbers leaked on Oct. 22—days before the scheduled ESMO presentation—traders were primed for a "sell-the-news" unwind, and that profit-taking has carried into this session.
Valuation Reset and Analyst Downgrade
Compounding the clinical disappointment is the stock's stretched valuation. After a 545% year-to-date surge, MRNA traded at roughly 39 to 42 times forward sales, far above its historical average. Against that backdrop, William Blair downgraded the shares to Market Perform from Outperform, explicitly citing valuation concerns even while acknowledging that intismeran's data could support a new standard of care. Other analysts were similarly cautious, with RBC Capital describing the results as at the "low end" of expectations and questioning the drug's commercial positioning relative to cheaper, off-the-shelf alternatives.
Market Context and Trading Activity
The slide in MRNA was a company-specific move rather than a reflection of broader risk-off sentiment. The iShares Biotechnology ETF (IBB) edged higher on the session, and the S&P 500 and Nasdaq were flat to modestly positive, underscoring that the weakness was concentrated in Moderna's single-platform mRNA exposure. Peer BioNTech slipped roughly 3% in sympathy, while diversified drugmakers such as Pfizer held relatively steady. Elevated volume accompanying the decline signaled persistent distribution as investors continued to reprice the commercial upside of the company's flagship oncology program.
What Comes Next for MRNA
Attention now shifts to a pair of earnings events that could clarify the path forward. Merck reports on Oct. 29, and MRNA follows on Nov. 6, with investors seeking details on regulatory filing plans, manufacturing economics, and the read-through to other tumor types such as lung, kidney, and bladder cancer. Key uncertainties include immature overall-survival data, whether the distant-metastasis benefit proves commercially meaningful, and whether insurers will embrace an individually manufactured vaccine. With the stock still priced for significant future success, any negative development in these areas could sustain the current volatility.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots spanning thousands of tickers. While Tickeron offers hundreds of bots, only the strongest performers under current market conditions are featured in this section, with strategies differing by timeframe, performance metrics, and the symbols they trade. Explore the page to see how automated systems are navigating today's markets.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MRNA in +8.34% Uptrend, advancing for three consecutive days on October 21, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MRNA advanced for three days, in 213 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Aroon Indicator entered an Uptrend today. In 101 of 132 cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Bearish Trend Analysis
The 10-day RSI Indicator for MRNA moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 23 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRNA as a result. In 73 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for MRNA turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 33 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
MRNA broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 1 (best 1 - 100 worst), indicating outstanding price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.742) is normal, around the industry mean (3.037). P/E Ratio (-24.919) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (25.907) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of transformative medicines for patients
Industry Biotechnology
Advertisement